Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants-The SPRING study

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Carbonell Estrany, Xavier ^a   Pérez Yarza, Eduardo G ^b,c,d   García, Laura Sanchez ^e   Cabañas, Juana M Guzmán ^f   Bòria, Elena Villarrubia ^g   Atienza, Belén Bernardo ^h  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g 3D Health Research   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGY; ARTICLE; CHILD; CHILD HOSPITALIZATION; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PREMATURITY; QUALITY OF LIFE; RECURRENT DISEASE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK FACTOR; WHEEZING; CASE CONTROL STUDY; COMPLICATION; GESTATIONAL AGE; HOSPITALIZATION; INFANT; INFANT, PREMATURE, DISEASES; NEWBORN; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PHYSIOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RESPIRATORY SOUNDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; VIROLOGY;

ANTIVIRUS AGENT; PALIVIZUMAB;

ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; PALIVIZUMAB; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; RESPIRATORY SOUNDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84949102396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125422     Document Type: Article

References (49)

1. Simões EA. Respiratory syncytial virus infection. Lancet. 1999; 354: 847-852. PMID: 10485741
2. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009; 360: 588-598. doi: 10.1056/ NEJMoa0804877 PMID: 19196675
3. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, et al. FLIP-2 Study: riskfactors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008; 27: 788-793. doi: 10.1097/INF.0b013e3181710990 PMID: 18664927
4. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004; 23: 806-814. PMID: 15361717
5. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, et al. Incidence and riskfactors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003 162:230-236. PMID: 12647195
6. Simões EA. Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res. 2002; 3 (Suppl 1): S26-S33. PMID: 12119055
7. Ambrose CS, Anderson EJ, Simões EA, Wu X, Elhefni H, Park CL, et al. Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32-35 Weeks Gestation Not Receiving Immunoprophylaxis. Pediatr Infect Dis J. 2014; 33: 576-582. doi: 10.1097/INF.0000000000000219 PMID: 24622396
8. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resources and outcomes. J Pediatr. 2003; 143: S133-S141. PMID: 14615712
9. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013; 368:1791-1799. doi: 10.1056/NEJMoa1211917 PMID: 23656644
10. Stensballe LG, Simonsen JB, Thomsen SF, Larsen AM, Lysdal SH, Aaby P, et al. The causal direction in the association between respiratory syncytial virus hospitalization and asthma. J Allergy Clin Immunol 2009; 123:131-137. doi: 10.1016/j.jaci.2008.10.042 PMID: 19130934
11. Carroll KN, Wu P, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, et al. Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma. J Allergy Clin Immunol. 2009; 123: 964-966. doi: 10.1016/j.jaci.2008.12.011 PMID: 19181372
12. Zomer-Kooijker K, van der Ent CK, Ermers MJ, Uiterwaal CS, Rovers MM, Bont LJ, et al. Increased risk of wheeze and decreased lung function after respiratory syncytial virus infection. PLoS One. 2014; 9: e87162. doi: 10.1371/journal.pone.0087162 PMID: 24498037
13. Escobar GJ, Masaquel AS, Li SX, Walsh EM, Kipnis P. Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy. BMC Pediatr. 2013; 13: 97. doi: 10.1186/1471-2431-13-97 PMID: 23782528
14. Takeyama A, Hashimoto K, Sato M, Sato T, Tomita Y, Maeda R, et al. Clinical and epidemiologic factors related to subsequent wheezing after virus-induced lower respiratory tract infections in hospitalized pediatric patients youngerthan 3 years. Eur J Pediatr. 2014; 173: 959-966. doi: 10.1007/s00431-014-2277-7 PMID: 24535712
15. Greenough A, Limb E, Marston L, Marlow N, Calvert S, Peacock J. Risk factors for respiratory morbidity in infancy after very premature birth. Arch Dis Child Fetal Neonatal. 2005; Ed 90: F320-323.
16. Escobar GJ, Ragins A, Li SX, Prager L, Masaquel AS, Kipnis P. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-conformed, medically attended infections with respiratory syncytial virus during the first year of life. Arch Pediatr Adolesc Med. 2010; 164: 915-922. doi: 10.1001/archpediatrics.2010.177 PMID: 20921348
17. Greenough A, Alexander J, Boit P, Boorman J, Burgess S, Burke A, et al. School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants. Thorax 2009; 64: 490-495. doi: 10.1136/thx.2008.095547 PMID: 19213770
18. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Björkstén B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995; 95: 500-505. PMID: 7700748
19. Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am J RespirCritCare Med. 2001; 163: 2-6. PMID: 11208613
20. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005; 171:137-141. PMID: 15516534
21. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010; 65:1045-1052. doi: 10.1136/thx.2009.121582 PMID: 20581410
22. Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM. Hospitalisation for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study. Pediatr Allergy Immunol. 2005; 16: 386-392. PMID: 16101930
23. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and riskofwheeze and allergy by age 13 years. Lancet. 1999; 354: 541-545. PMID: 10470697
24. Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012; 130: 91-100. doi: 10. 1016/j.jaci.2012.02.010 PMID: 22444510
25. Bont L, Steijn M, Van Aalderen WM, Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J. 2004; 23: 414-417. PMID: 15131463
26. Shefali-Patel D, Paris MA, Watson F, Peacock JL, Campbell M, Greenough A. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012; 171:1055-1061. doi: 10.1007/s00431-012-1673-0 PMID: 22302458
27. Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group, et al. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004; 23: 815-820. PMID: 15361718
28. Fekkes M, Theunissen NC, Brugman E, Veen S, Verrips EG, Koopman HM, et al. Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1-5-year-old children. Qual Life Res. 2000; 9: 961-972. PMID: 11284215
29. Sardón Prado O, Morera G, Herdman M, Moreno GaldóA, Pérez-Yarza EG, DetmarS, et al. Versión española del TAPQOL: calidad de vida relacionada con la salud en niños de 3 meses a 5 años. An Pediatr (Barc). 2008; 68: 420-424. PMID: 18447984
30. Rajmil L, Abad S, Sardon O, Morera G, Pérez-Yarza EG, Moreno A, et al. Reliability and validity of the Spanish version of the TAPQOL: A health-related quality of life (HRQOL) instrument for 1- to 5-year-old children. Int J Nurs Stud. 2011; 48: 549-556. doi: 10.1016/j.ijnurstu.2010.09.004 PMID: 20951379
31. Miller MR, Hankinson J, Brusasco V, Brusasco V, Burgos F, Casaburi R, et al. Standardisation of spirometry. Eur Respir J. 2005; 26: 319-338. PMID: 16055882
32. Oppenheimer J, Nelson HS. Skin testing. Ann Allergy Asthma Immunol. 2006; 96(2 Suppl 1): S6-S12. PMID: 16496505
33. Høst A, Andrae S, Charkin S, Diaz-Vázquez C, Dreborg S, Eigenmann PA, et al. Allergy testing in children: why, who, when and how? Allergy. 2003; 58: 559-569. PMID: 12823111
34. Simões EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007; 151: 34-42. PMID: 17586188
35. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012; 40: 1324-1343. doi: 10.1183/09031936.00080312 PMID: 22743675
36. Kneyber MCJ, Steyerberg EW, de Groot R, Moll HA. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. Acta Paediatr. 2000; 89: 654-660. PMID: 10914957
37. Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Simões EA, et al. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 2013; 132: 811-818. doi: 10. 1542/peds.2013-0982 PMID: 24127479
38. Régnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J. 2013; 32: 820-826. doi: 10.1097/INF.0b013e31829061e8 PMID: 23518824
39. Szabo SM, Levy AR, Gooch KL, Bradt P, Wijaya H, Mitchell I. Elevated risk of asthma after hospitalization for respiratory syncytial virus infection in infancy. Paediatr Respir Rev. 2013; 13 Suppl 2: S9-15. doi: 10.1016/S1526-0542(12)70161-6 PMID: 23269182
40. Drysdale SB, Prendergast M, Alcazar M, Wilson T, Smith M, Zuckerman M, et al. Genetic predisposition of RSV infection-related respiratory morbidity in preterm infants. Eur J Pediatr. 2014; 173: 905-912. doi: 10.1007/s00431-014-2263-0 PMID: 24487983
41. Tapia LI, AmpueroS, Palomino MA, Luchsinger V, Aguilar N, Ayarza E, et al. Respiratory syncytial virus infection and recurrent wheezing in Chilean infants: a genetic background? Infect Genet Evol. 2013; 16: 54-61. doi: 10.1016/j.meegid.2012.12.030 PMID: 23333336
42. Martinez FD1, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995; 332:133-138. PMID: 7800004
43. Collins SA, Pike KC, Inskip HM, Godfrey KM, Roberts G, Holloway JW, et al. Validation of novel wheeze phenotypes using longitudinal airway function and atopic sensitization data in the first 6 years of life: evidence from the Southampton Women's survey. Pediatr Pulmonol. 2013; 48:683-692. doi: 10. 1002/ppul.22766 PMID: 23401430
44. Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR, et al. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol. 2010; 126: 256-262. doi: 10.1016/j.jaci.2010.05.026 PMID: 20624638
45. Friedrich L, Stein RT, Pitrez PM, Corso AL, Jones MH. Reduced lung function in healthy infants in the first months of life. Am J Respir Crit Care Med. 2006; 173: 442-447. PMID: 16322648
46. Kotecha SJ, Edwards MO, Watkins WJ, Henderson AJ, Paranjothy S, Dunstan FD, et al. Effect of preterm birth on later FEV1: a systematic review and meta-analysis. Thorax. 2013; 68: 760-766. doi: 10.1136/thoraxjnl-2012-203079 PMID: 23604458
47. Friedrich L, Pitrez PM, Stein RT, Goldani M, Tepper R, Jones MH. Growth rate of lung function in healthy preterm infants. Am J Respir Crit Care Med. 2007; 176:1269-1273. PMID: 17885265
48. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102: 531-537. PMID: 9738173
49. Colin AA, McEvoy C, Castile RG. Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age. Pediatrics. 2010; 126:115-128. doi: 10.1542/peds.2009-1381 PMID: 20530073